Healio
Healio
21003793_EF156_THin_MM_collection_banner

Take Homes in Multiple Myeloma
ByAdam D. Cohen, MD
ByGeorgia I Salvaryn
Fact checked byMindy Valcarcel, MS

Read more

June 25, 2024
2 min watch
Save

VIDEO: MRD testing determines therapy cessation for patients with multiple myeloma

ByAdam D. Cohen, MD
ByGeorgia I Salvaryn
Fact checked byMindy Valcarcel, MS

CHICAGO — In this video, Adam Cohen, MD, spoke to Healio about the use of minimal residual disease testing to determine cessation of therapy in patients with multiple myeloma.

The MRD2STOP trial, presented at ASCO Annual Meeting, observed multiple factors in patients to determine the discontinuation of maintenance therapy.

“This was a small study that needs to be confirmed in larger numbers,” Cohen, associate professor of medicine in hematology-oncology at Hospital of the University of Pennsylvania, said. “But I think this is exciting data. And I think this will allow us eventually to become smarter about how we are going to treat our patients [and] how long we have to treat them.”

Reference:

  • Derman BA, et al. Abstract 106. Presented at: ASCO Annual Meeting; May 31-June 4, 2024; Chicago.
Sources/Disclosures

Collapse
Source:

Healio Interviews

Disclosures: Cohen reports serving as a consultant for AstraZeneca, Bristol Myers Squibb, Genentech/Roche, GSK, Ichnos, iTeos, Janssen, Pfizer and Sanofi; receiving funding from Genentech/Roche, GSK, Janssen and Novartis; and having patents with Novartis.

Read more about

multiple myeloma
minimal residual disease
 

Related Content